| dazodalibep (HZN-4920) / Amgen |
2019-002351-42: Observational Study of VIB4920 to Evaluate the Duration of Clinical and Pharmacodynamic Efficacy of VIB4920 |
|
|
| Not yet recruiting | 3 | 17 | Europe | | Viela Bio, Inc., Viela Bio Inc. | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
HZNP-DAZ-303, NCT06245408: A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State |
|
|
| Recruiting | 3 | 435 | Europe, Canada, Japan, US, RoW | Dazodalibep, VIB 4920, MEDI4920, Placebo | Amgen | Sjögren's Syndrome (SS) | 08/26 | 08/26 | | |
NCT06747949: A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) |
|
|
| Not yet recruiting | 3 | 844 | NA | Dazodalibep, AMG 611 | Amgen | Sjögren's Syndrome | 07/29 | 07/29 | | |
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity |
|
|
| Recruiting | 3 | 621 | Europe, Canada, Japan, US, RoW | Dazodalibep, VIB 4920, MEDI 4920, Placebo | Amgen | Sjogren's Syndrome | 07/26 | 07/26 | | |
2019-003697-70: A study to look at the effectiveness and safety of test product VIB4920 insubjects with Rheumatoid Arthritis (RA) |
|
|
| Not yet recruiting | 2 | 75 | Europe | VIB4920, Concentrate for solution for infusion | Viela Bio, Inc., Viela Bio, Inc. | Rheumatoid Arthritis, Rheumatoid Arthritis, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
NCT04046549: A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant |
|
|
| Completed | 2 | 25 | US | Belatacept, VIB4920, Thymoglobulin, Methylprednisolone | Amgen | Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation | 07/22 | 03/23 | | |
| Completed | 2 | 183 | Europe, US, RoW | VIB4920, Dazodalibep, Placebo | Amgen | Sjögren's Syndrome | 09/22 | 03/23 | | |
| Active, not recruiting | 2 | 104 | NA | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Rheumatoid Arthritis | 08/25 | 03/26 | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
